Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma

BEA-17Positive

AI Analysis

Summary

Beactica Therapeutics AB announced initiation of IND-enabling studies for BEA-17, a first-in-class oral degrader of LSD1 and CoREST for glioblastoma treatment.

Outcome Details

IND-enabling studies initiated

Importance:3/10

Sentiment:

0.50

early-stage developmentfirst-in-classepigeneticglioblastomaoral degrader

Related Companies

$DTIL $SHWZ $SOBI.ST $TRAX

Read the original article

Published by PR Newswire Biotech on September 22, 2026 6:22 AM

Read Original